Ignite Creation Date:
2024-05-05 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00425035
Status:
COMPLETED
Last Update Posted:
2013-05-13
First Post:
2007-01-18
Brief Title:
Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer Part 2
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Two-part Multiple Dose Clinical Trial Evaluating the Safety and Effectiveness of ABX-EGF in Patients With Renal Carcinoma
Status:
COMPLETED
Status Verified Date:
2013-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multicenter 2-part multiple-dose study designed to evaluate the safety and effectiveness of weekly administration of panitumumab in subjects with renal carcinoma Part 1 was initiated in 2001 and will not be presented here Part 2 was designed to examine a dose of 25 mgkgwk in 2 cohorts
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Immunex protocol No 0540003 | None | None | None |
| Abgenix protocol No ABX-0303 | None | None | None |